Picard Medical (PMI) CEO to present Emperor Total Artificial Heart data at CSI Focus D-HF 2025

Rhea-AI Filing Summary

Picard Medical, Inc. reported that its CEO, Patrick NJ Schnegelsberg, will present data on the company’s Emperor Total Artificial Heart at the CSI Focus D-HF (Device Therapies in Heart Failure) conference. The event is scheduled for December 5 and 6, 2025, in Frankfurt, Germany, giving the company an opportunity to share clinical or technical information about its artificial heart technology with a specialized cardiovascular audience.

The update is being shared through a press release furnished as an exhibit to this current report, and is characterized as supplemental information that is not deemed filed for liability purposes under federal securities laws.

false 0002030617 0002030617 2025-12-03 2025-12-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 3, 2025

 2025-11-25

Picard Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42801		86-3212894
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1992 E Silverlake Tucson AZ, 85713

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (520) 545-1234

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PMI		The NYSE American, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On December 3, 2025, Picard Medical, Inc. issued a press release announcing that its CEO, Patrick NJ Schnegelsberg, will present data on the Emperor Total Artificial Heart at the CSI Focus D-HF (Device Therapies in Heart Failure) conference. The conference is scheduled for December 5 and 6, 2025, in Frankfurt, Germany. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference herein.

The information in this report and the exhibits attached hereto shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1		Picard Medical, Inc. Press Release dated December 3, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Picard Medical, Inc.
By:	/s/ Patrick NJ Schnegelsberg
	Name:	Patrick NJ Schnegelsberg
	Title:	Chief Executive Officer

Dated: December 3, 2025

2

FAQ

What did Picard Medical, Inc. (PMI) announce in this 8-K filing?

Picard Medical, Inc. announced that its CEO, Patrick NJ Schnegelsberg, will present data on the Emperor Total Artificial Heart at the CSI Focus D-HF conference, with details provided in a furnished press release.

When and where will Picard Medical (PMI) present the Emperor Total Artificial Heart data?

The CEO of Picard Medical will present data on the Emperor Total Artificial Heart at the CSI Focus D-HF conference scheduled for December 5–6, 2025, in Frankfurt, Germany.

Who from Picard Medical (PMI) is presenting at the CSI Focus D-HF conference?

Picard Medical’s Chief Executive Officer, Patrick NJ Schnegelsberg, is scheduled to present the data at the CSI Focus D-HF conference.

What technology is Picard Medical (PMI) highlighting in this announcement?

The announcement highlights Picard Medical’s Emperor Total Artificial Heart, which is the subject of the data presentation at the CSI Focus D-HF conference.

Is the information about Picard Medical’s conference presentation considered filed under securities laws?

The company states that the information in this report and its exhibits is furnished, not filed, and is not subject to the liabilities associated with filed information under the Securities Exchange Act of 1934.

What exhibit did Picard Medical (PMI) include with this 8-K?

Picard Medical included Exhibit 99.1, which is the press release dated December 3, 2025, along with a Cover Page Interactive Data File identified as Exhibit 104.